UBS Group
PBLS

UBS Group’s Parabilis Medicines Inc PBLS Stock Holding History

UBS Group’s Portfolio PBLS Stock Details PBLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Buy
+38,698
New +$1.07M ﹤0.01% 5685

Other funds holding PBLS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

UBS Group's PBLS Position: Q2 2026 in Review

UBS Group opened a new position in Parabilis Medicines Inc (PBLS) in Q2 2026: 38,698 shares worth $1.06M. The stake represents ﹤0.01% of the portfolio and ranks #5685 among its holdings.

79 funds tracked by Wall St. Rank hold PBLS as of Q2 2026.

  • UBS Group held 38,698 shares of Parabilis Medicines Inc worth $1.06M as of Q2 2026.
  • Parabilis Medicines Inc was a new UBS Group position in Q2 2026.
  • Parabilis Medicines Inc made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #5685 holding.
  • 79 funds tracked by Wall St. Rank held Parabilis Medicines Inc as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.